Ирина Николаевна Мамчур
Ирина Николаевна Мамчур has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Sergey E. Mamchur
FSBI “Research Institute for Complex Issues of Cardiovascular Diseases
6 shared publications - Ol'Ga Leonidovna Barbarash
Federal State Budgetary Scientific Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, Academician L.S. Barbarash Boulevard, 6, Kemerovo 650002, Russia
3 shared publications - Zakir Z. Khalimov
Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases
3 shared publications - Anastasiya G. Neeshpapa
Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo 650002, Russia
2 shared publications - Egor A. Khomenko
Research Institute for Complex Issues of Cardiovascular Diseases
2 shared publications - Evgeniya A. Shmidt
Research Institute for Complex Issues of Cardiovascular Diseases
2 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (5) , 92-102
RESULTS OF TRANSCATHETER REPROSTHETICS OF THE AORTIC VALVE
Highlights The study demonstrates the possibility of successful repeated endovascular intervention in case of dysfunction of a previously implanted bioprosthesis, which opens up new prospects in the treatment of patients with complications after aortic valve replacement. The study showed the high efficiency and safety of the method: technical success was achieved in all 8 cases, while no deaths, strokes or other serious complications were recorded during the 12 months of follow-up. The clinical effectiveness of the method is confirmed by the positive dynamics of EchoCG parameters (reduction of pressure gradient, disappearance of severe regurgitation, reduction of LV hypertrophy) and improvement of patients’ condition. Aim . To evaluate the safety and effectiveness of transcatheter prosthetics of the aortic valve (TPAK) using the valve-in-valve method in patients with bioprosthesis dysfunction in the aortic position based on the analysis of the results of the first endovascular reprosthetics procedures at the Scientific Research Institute of Complex Problems of Cardiovascular Diseases (NII KPSSZ). Methods . The present study included 8 patients with aortic bioprosthesis dysfunction who underwent valve-to-valve transfemoral access during this time period. Of the 8 valve-to-valve surgical procedures, 7 endovascular interventions were performed due to the development of dysfunctions of biological prostheses in the aortic position after open surgery and in 1 case after the primary surgical procedure. Average STS Score = 8.4%. The main types of dysfunction were primary tissue failure with rupture of xenospores and the formation of insufficiency (n = 5) and calcium degeneration of the biological valve with the appearance of a stenotic effect (n = 3). The endpoints were evaluated for efficiency and safety and were divided into 3 blocks: 1) Clinical results; 2) Complications; 3) EchoCG data. The results were evaluated 30 days after the intervention and after 12 months. Results . The average duration of aortic valve function after primary arthroplasty until the first signs of dysfunction was 5.3 (3.1; 11.9) years. After valve-to-valve TPA with transfemoral access, death from all causes, cardiovascular death, periprocedural death, stroke, TIA, myocardial infarction, vascular complications, cardiac complications, bleeding (on the BARC scale), arrhythmological events, prosthetic dysfunction requiring reoperative, infectious endocarditis were not noted not in any case. The technical success of TPAC, which was assessed only during the period of hospitalization, was noted in all cases. Only one patient (16.67%) was hospitalized for CHF decompensation at the 12-month follow-up stage with satisfactory indicators of aortic bioprosthesis function according to EchoCG. According to the EchoCG data between the period before reprosthetics and 12 months after, there was a significant positive trend in terms of maximum velocity and maximum gradient per AC. At the same time, the changes in the average velocity and average gradient were not significant. Grade III–IV transprosthetic regurgitation before reprosthetics was observed in 4 patients (50%), and in dynamics it disappeared (only grade I regurgitation or its complete absence is noted), as well as regurgitation on grade III–IV MK was observed in 5 patients (62.5%), and in dynamics it disappeared (regurgitation is noted only of I and II degrees). LV hypertrophy became less pronounced in dynamics (average myocardial mass index after TPAK = 109.5 g/m 2 ). Conclusion . After valve-to-valve TPA with transfemoral access performed at the KPSSZ Research Institute, favorable results were shown after 30 days and 12 months. The low number of intra- and postoperative complications, the positive dynamics of the clinical status of patients and structural and functional parameters assessed by EchoCG led to a positive conclusion on the safety and effectiveness of the presented method of treatment of patients with aortic bioprosthesis dysfunction.
- 31 October 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (5) , 92-102
Open AccessRESULTS OF TRANSCATHETER REPROSTHETICS OF THE AORTIC VALVE
Highlights The study demonstrates the possibility of successful repeated endovascular intervention in case of dysfunction of a previously implanted bioprosthesis, which opens up new prospects in the treatment of patients with complications after aortic valve replacement. The study showed the high efficiency and safety of the method: technical success was achieved in all 8 cases, while no deaths, strokes or other serious complications were recorded during the 12 months of follow-up. The clinical effectiveness of the method is confirmed by the positive dynamics of EchoCG parameters (reduction of pressure gradient, disappearance of severe regurgitation, reduction of LV hypertrophy) and improvement of patients’ condition. Aim . To evaluate the safety and effectiveness of transcatheter prosthetics of the aortic valve (TPAK) using the valve-in-valve method in patients with bioprosthesis dysfunction in the aortic position based on the analysis of the results of the first endovascular reprosthetics procedures at the Scientific Research Institute of Complex Problems of Cardiovascular Diseases (NII KPSSZ). Methods . The present study included 8 patients with aortic bioprosthesis dysfunction who underwent valve-to-valve transfemoral access during this time period. Of the 8 valve-to-valve surgical procedures, 7 endovascular interventions were performed due to the development of dysfunctions of biological prostheses in the aortic position after open surgery and in 1 case after the primary surgical procedure. Average STS Score = 8.4%. The main types of dysfunction were primary tissue failure with rupture of xenospores and the formation of insufficiency (n = 5) and calcium degeneration of the biological valve with the appearance of a stenotic effect (n = 3). The endpoints were evaluated for efficiency and safety and were divided into 3 blocks: 1) Clinical results; 2) Complications; 3) EchoCG data. The results were evaluated 30 days after the intervention and after 12 months. Results . The average duration of aortic valve function after primary arthroplasty until the first signs of dysfunction was 5.3 (3.1; 11.9) years. After valve-to-valve TPA with transfemoral access, death from all causes, cardiovascular death, periprocedural death, stroke, TIA, myocardial infarction, vascular complications, cardiac complications, bleeding (on the BARC scale), arrhythmological events, prosthetic dysfunction requiring reoperative, infectious endocarditis were not noted not in any case. The technical success of TPAC, which was assessed only during the period of hospitalization, was noted in all cases. Only one patient (16.67%) was hospitalized for CHF decompensation at the 12-month follow-up stage with satisfactory indicators of aortic bioprosthesis function according to EchoCG. According to the EchoCG data between the period before reprosthetics and 12 months after, there was a significant positive trend in terms of maximum velocity and maximum gradient per AC. At the same time, the changes in the average velocity and average gradient were not significant. Grade III–IV transprosthetic regurgitation before reprosthetics was observed in 4 patients (50%), and in dynamics it disappeared (only grade I regurgitation or its complete absence is noted), as well as regurgitation on grade III–IV MK was observed in 5 patients (62.5%), and in dynamics it disappeared (regurgitation is noted only of I and II degrees). LV hypertrophy became less pronounced in dynamics (average myocardial mass index after TPAK = 109.5 g/m 2 ). Conclusion . After valve-to-valve TPA with transfemoral access performed at the KPSSZ Research Institute, favorable results were shown after 30 days and 12 months. The low number of intra- and postoperative complications, the positive dynamics of the clinical status of patients and structural and functional parameters assessed by EchoCG led to a positive conclusion on the safety and effectiveness of the presented method of treatment of patients with aortic bioprosthesis dysfunction.
- Open Access
- 30 January 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (2) , 4301
Relationship between epicardial/visceral obesity and myocardial remodeling characteristics in patients with acquired mitral valve disease
Связь эпикардиального и висцерального ожирения с характером ремоделирования миокарда у пациентов с приобретенным пороком митрального клапана
- 30 January 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (2) , 4301
Open AccessRelationship between epicardial/visceral obesity and myocardial remodeling characteristics in patients with acquired mitral valve disease
Связь эпикардиального и висцерального ожирения с характером ремоделирования миокарда у пациентов с приобретенным пороком митрального клапана
- Open Access
- 28 December 2024
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 13 (4S) , 267-275
HYPERTROPHIC CARDIOMYOPATHY IN TEENAGER WITH LEOPARD SYNDROME (CLINICAL CASE)
HighlightsThis review describes a rare clinical case of hypertrophic cardiomyopathy in a teenager with LEOPARD syndrome. AbstractHypertrophic cardiomyopathy (HCM) is a genetically determined cardiac disease which can be caused by nearly 1500 genetic mutations, encoding proteins of the cardiac sarcomere and some non-sacromeric proteins. There is a number of hereditary metabolic disorders and diseases which can imitate phenotype and clinical picture of HCM. Abnormalities with systemic symptoms are usually identified as a syndrome, including hypertrophic myocardium signs. Such abnormalities are regarded to the RASopathies, a group of phenotypically similar genetic syndromes. Nowadays RASopathies include 1-type neurofibromatosis, Noonan syndrome, LEOPARD syndrome, Costello syndrome, Legius syndrome, cardiofaciocutaneous syndrome, and capillary malformation-arteriovenous malformation syndrome.
- 28 December 2024
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 13 (4S) , 267-275
Open AccessHYPERTROPHIC CARDIOMYOPATHY IN TEENAGER WITH LEOPARD SYNDROME (CLINICAL CASE)
HighlightsThis review describes a rare clinical case of hypertrophic cardiomyopathy in a teenager with LEOPARD syndrome. AbstractHypertrophic cardiomyopathy (HCM) is a genetically determined cardiac disease which can be caused by nearly 1500 genetic mutations, encoding proteins of the cardiac sarcomere and some non-sacromeric proteins. There is a number of hereditary metabolic disorders and diseases which can imitate phenotype and clinical picture of HCM. Abnormalities with systemic symptoms are usually identified as a syndrome, including hypertrophic myocardium signs. Such abnormalities are regarded to the RASopathies, a group of phenotypically similar genetic syndromes. Nowadays RASopathies include 1-type neurofibromatosis, Noonan syndrome, LEOPARD syndrome, Costello syndrome, Legius syndrome, cardiofaciocutaneous syndrome, and capillary malformation-arteriovenous malformation syndrome.
- Open Access
- 23 August 2024
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
Comparative characteristics of endovascular occlusion and thoracoscopic amputation of left atrial appendage in patients with atrial fibrillation
Aim. To compare the effectiveness and safety of endovascular occlusion and thoracoscopic amputation of the left atrial appendage (LAA) in patients with atrial fibrillation (AF).Methods. We present a retrospective single-center study with a prospective component including 25 patients with AF who underwent thoracoscopic amputation of the LAA and 31 patients on prospective part who underwent endovascular occlusion of the LAA. All patients signed voluntary informed consent for medical intervention and participation in the study. The criteria for selecting patients for thoracoscopic amputation of the LAA were the impossibility of performing an endovascular technique, features of its anatomy and increased trabecularity.Results. In the group of patients with thoracoscopic amputation of the LAA, 2 cases of embologenic stump of the LAA with a depth of 1.6 cm (8%) were identified; these patients were recommended to continue taking anticoagulant therapy. Among patients who underwent thoracoscopic amputation, no complications were identified in the first 30 days after surgery, including mortality, bleeding, phrenic nerve paresis, acute cerebrovascular accident, pleurisy, pneumothorax, hemothorax. In 3 patients who underwent endovascular occlusion of the LAA, hematomas were detected at the site of puncture of the great vessels (9.7%), in 2 patients thrombus were detected on the occlusion device according to the results of transesophageal echocardiography (6.5%), which required the prescription of warfarin in these patients. Also, in 2 patients (6.5%) during implantation of the occluder into the LAA, as a result of the incorrect diameter of the disk of the occluding device, a residual cavity with a depth of 0.7 cm was formed between the ridge and the occluder. No significant differences in the frequency of non-severe complications were found in the groups, p =0.139. During the year of postoperative observation, thromboembolic complications were absent in the operated patients of both groups.Conclusion. When comparing two methods of LAA isolation, no severe complications were identified, either in the perioperative or in the early or late postoperative period. There were no significant differences in the incidence of non-severe complications in the early postoperative period. Thus, the effectiveness and safety of thoracoscopic amputation and endovascular occlusion of the left atrial appendage are comparable.
- 23 August 2024
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
Open AccessComparative characteristics of endovascular occlusion and thoracoscopic amputation of left atrial appendage in patients with atrial fibrillation
Aim. To compare the effectiveness and safety of endovascular occlusion and thoracoscopic amputation of the left atrial appendage (LAA) in patients with atrial fibrillation (AF).Methods. We present a retrospective single-center study with a prospective component including 25 patients with AF who underwent thoracoscopic amputation of the LAA and 31 patients on prospective part who underwent endovascular occlusion of the LAA. All patients signed voluntary informed consent for medical intervention and participation in the study. The criteria for selecting patients for thoracoscopic amputation of the LAA were the impossibility of performing an endovascular technique, features of its anatomy and increased trabecularity.Results. In the group of patients with thoracoscopic amputation of the LAA, 2 cases of embologenic stump of the LAA with a depth of 1.6 cm (8%) were identified; these patients were recommended to continue taking anticoagulant therapy. Among patients who underwent thoracoscopic amputation, no complications were identified in the first 30 days after surgery, including mortality, bleeding, phrenic nerve paresis, acute cerebrovascular accident, pleurisy, pneumothorax, hemothorax. In 3 patients who underwent endovascular occlusion of the LAA, hematomas were detected at the site of puncture of the great vessels (9.7%), in 2 patients thrombus were detected on the occlusion device according to the results of transesophageal echocardiography (6.5%), which required the prescription of warfarin in these patients. Also, in 2 patients (6.5%) during implantation of the occluder into the LAA, as a result of the incorrect diameter of the disk of the occluding device, a residual cavity with a depth of 0.7 cm was formed between the ridge and the occluder. No significant differences in the frequency of non-severe complications were found in the groups, p =0.139. During the year of postoperative observation, thromboembolic complications were absent in the operated patients of both groups.Conclusion. When comparing two methods of LAA isolation, no severe complications were identified, either in the perioperative or in the early or late postoperative period. There were no significant differences in the incidence of non-severe complications in the early postoperative period. Thus, the effectiveness and safety of thoracoscopic amputation and endovascular occlusion of the left atrial appendage are comparable.
- Open Access
- 29 March 2024
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 13 (1) , 116-121
THORACOSCOPIC LEFT ATRIAL APPENDAGE AMPUTATION CAN BE AN ALTERNATIVE TO ENDOVASCULAR OCCLUSION
HighlightsWe present a clinical case of a patient with atrial fibrillation and a high bleeding risk according to HAS-BLED bleeding risk score who underwent thoracoscopic left atrial appendage (LAA) occluder implantation due to lack of endovascular access. Thoracoscopic amputation of LAA also can be performed in cases where an endovascular access cannot be achieved due to occlusion of the inferior vena cava or thrombosis of LAA. However, it is necessary to monitor the condition of the stump when conducting thoracoscopic amputation of LAA, and stop anticoagulation therapy only in case of non-embologenic stump. AbstractAtrial fibrillation is the most common rhythm disorder that can be conservatively treated using antiarrhythmic therapy, and anticoagulants can be used to prevent thromboembolic complications. However, prolonged use of anticoagulants is complicated by the risk of bleeding. Left atrial appendage (LAA) occluder implantation is an alternative way of preventing of thromboembolic and hemorrhagic complications. The article presents a clinical case of thoracoscopic LAA amputation after unsuccessful endovascular LAA occluder implantation in the patient with the inferior vena cava occlusion.
- 29 March 2024
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 13 (1) , 116-121
Open AccessTHORACOSCOPIC LEFT ATRIAL APPENDAGE AMPUTATION CAN BE AN ALTERNATIVE TO ENDOVASCULAR OCCLUSION
HighlightsWe present a clinical case of a patient with atrial fibrillation and a high bleeding risk according to HAS-BLED bleeding risk score who underwent thoracoscopic left atrial appendage (LAA) occluder implantation due to lack of endovascular access. Thoracoscopic amputation of LAA also can be performed in cases where an endovascular access cannot be achieved due to occlusion of the inferior vena cava or thrombosis of LAA. However, it is necessary to monitor the condition of the stump when conducting thoracoscopic amputation of LAA, and stop anticoagulation therapy only in case of non-embologenic stump. AbstractAtrial fibrillation is the most common rhythm disorder that can be conservatively treated using antiarrhythmic therapy, and anticoagulants can be used to prevent thromboembolic complications. However, prolonged use of anticoagulants is complicated by the risk of bleeding. Left atrial appendage (LAA) occluder implantation is an alternative way of preventing of thromboembolic and hemorrhagic complications. The article presents a clinical case of thoracoscopic LAA amputation after unsuccessful endovascular LAA occluder implantation in the patient with the inferior vena cava occlusion.
- Open Access
- 17 October 2023
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 30 (4) , 6-10
Thoracoscopic ablation of persistent atrial fibrillation after left atrial appendage occluder implantation: a case report
A clinical case of successful radiofrequency thoracoscopic ablation of persistent atrial fibrillation after implantation of an occluder in the left atrium appendage is presented.
- 17 October 2023
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 30 (4) , 6-10
Open AccessThoracoscopic ablation of persistent atrial fibrillation after left atrial appendage occluder implantation: a case report
A clinical case of successful radiofrequency thoracoscopic ablation of persistent atrial fibrillation after implantation of an occluder in the left atrium appendage is presented.
- Open Access
- 13 November 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (5) , 2423
Features of in-hospital clinical course of pulmonary embolism in patients of different age groups
Aim. To study the clinical course and management of patients with pulmonary embolism (PE) of various age groups hospitalized in a cardiology hospital. Material and methods. This prospective single-center study in the period from 2016 to 2018 included 154 patients with PE verified by computed tomography. Statistical processing was conducted using the MedCalcVersion 16.2.1 software package (Softwa, Belgium). Results. In all groups, female patients dominated, but the highest number of women (70,7%) belonged to the group of senile patients, while in the group Conclusion. In the Kemerovo Oblast, PE most often develops in patients aged 60-75 years and is characterized by a more severe clinical course compared with patients younger than 60 years. Patients over the 60 years of age have severe cardiovascular comorbidity status, atrial fibrillation/flutter and recurrent PE. Surgical treatment for senile patients is limited due to the high risk of postoperative complications, which specifies high mortality. Patients <60 years of age are a third of all patients hospitalized with PE. They have a low risk of mortality, but have an unfavorable course of the hospital period.
- 13 November 2020
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 19 (5) , 2423
Open AccessFeatures of in-hospital clinical course of pulmonary embolism in patients of different age groups
Aim. To study the clinical course and management of patients with pulmonary embolism (PE) of various age groups hospitalized in a cardiology hospital. Material and methods. This prospective single-center study in the period from 2016 to 2018 included 154 patients with PE verified by computed tomography. Statistical processing was conducted using the MedCalcVersion 16.2.1 software package (Softwa, Belgium). Results. In all groups, female patients dominated, but the highest number of women (70,7%) belonged to the group of senile patients, while in the group Conclusion. In the Kemerovo Oblast, PE most often develops in patients aged 60-75 years and is characterized by a more severe clinical course compared with patients younger than 60 years. Patients over the 60 years of age have severe cardiovascular comorbidity status, atrial fibrillation/flutter and recurrent PE. Surgical treatment for senile patients is limited due to the high risk of postoperative complications, which specifies high mortality. Patients <60 years of age are a third of all patients hospitalized with PE. They have a low risk of mortality, but have an unfavorable course of the hospital period.
- 27 September 2020
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 3,p. 21-28
Неблагоприятное течение тромбоэмболии легочной артерии в течение года наблюдения
Цель исследования: изучение частоты и причины неблагоприятных исходов, а также факторов, с ними связанных, в течение года наблюдения у пациентов с тромбоэмболией легочной артерии (ТЭЛА). Материалы и методы: В одноцентровый регистр проспективного наблюдения методом сплошного включения включены 185 пациентов с ТЭЛА. Проводилось стандартное обследование пациентов, диагноз подтверждался по результатам мультиспиральной компьютерной томографии. Период наблюдения составил 12 мес, в течение которого отслеживали исходы пациентов, выписанных под амбулаторное наблюдение. Конечными точками являлись все случаи смерти и рецидивов ТЭЛА. Статистическую обработку результатов осуществляли с помощью пакета программ MedCalc Version 16.2.1 (Softwa, Бельгия). Результаты: Годовые исходы были определены у 161 пациента. Фатальный исход в течение года после выписки из стационара наступил у 22 (13,6%) больных ТЭЛА: у 45,5% по причине рецидива ТЭЛА, у 22,7% — онкологической патологии, у 13,6% — из-за острого нарушения мозгового кровообращения (ОНМК). Развитие летальных исходов было ассоциировано с такими факторами, как пожилой возраст, наличие ишемической болезни сердца, злокачественных новообразований, застойной сердечной недостаточности, ОНМК, а также со снижением глобальной сократимости миокарда левого желудочка, высоким риском по шкале PESI (англ. Pulmonary Embolism Severity Index) и отказом от антикоагулянтной терапии в течение первых 6 мес. Рецидив ТЭЛА в течение года наблюдения выявлен в 11,2% случаев и был связан с наличием тромбоза глубоких вен нижних конечностей, нижней полой вены и подвздошных вен, застойной сердечной недостаточностью и дилатацией правых отделов сердца. Установлено, что отказ от антикоагулянтной терапии в течение 11 мес после первичного эпизода повышает риск развития рецидива ТЭЛА. Заключение: У пациентов с ТЭЛА в течение первого года наблюдения летальный исход развился в 13,6% случаев, а рецидив ТЭЛА — в 11,2%. Наиболее значимым неблагоприятным фактором, связанным с данными конечными точками, являлся отказ от антикоагулянтной терапии ранее 6 мес после эпизода ТЭЛА. Objectives: to study the incidence, causes and factors associated with adverse outcomes in patients with pulmonary embolism (PE) during the year of observation. Patients/Methods: The single-center prospective follow-up register included 185 patients with PE. Standard examination was carried out; the diagnosis was confirmed by multispiral computed tomography. During follow-up period of 12 months we tracked outpatient outcomes. The endpoints were all-cause mortality and PE relapses. Statistical analysis was performed by MedCalc Version 16.2.1 software package (Softwa, Belgium). Results: Twelve-month outcomes were determined in 161 patients. Post-discharge fatal outcome within a year occurred in 22 (13.6%) patients with PE: in 45.5% due to PE relapse, in 22.7% due to oncological pathology, in 13.6% because of acute stroke. Lethal outcomes were associated with elderly age, ischemic heart disease, malignant neoplasms, congestive heart failure, stroke, reduction of left ventricular global myocardial contractility, a high risk according to PESI (Pulmonary Embolism Severity Index) scale and the refusal of anticoagulant therapy during the first 6 months. Within a year of observation PE relapse was detected in 11.2% of patients and was associated with deep vein thrombosis of the lower limbs, inferior vena cava and iliac veins, congestive heart failure and dilatation of right heart compartments. Refusal of anticoagulant therapy within 11 months after the initial episode increased the risk of PE relapse. Conclusions: In patients with PE during the first year of observation a fatal outcome occurred in 13.6% patients with PE and PE relapse — in 11.2%. Refusal of anticoagulant therapy earlier than 6 months after the episode of PE was the most significant adverse factor associated with these endpoints.
- 27 September 2020
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 3,p. 21-28
Неблагоприятное течение тромбоэмболии легочной артерии в течение года наблюдения
Цель исследования: изучение частоты и причины неблагоприятных исходов, а также факторов, с ними связанных, в течение года наблюдения у пациентов с тромбоэмболией легочной артерии (ТЭЛА). Материалы и методы: В одноцентровый регистр проспективного наблюдения методом сплошного включения включены 185 пациентов с ТЭЛА. Проводилось стандартное обследование пациентов, диагноз подтверждался по результатам мультиспиральной компьютерной томографии. Период наблюдения составил 12 мес, в течение которого отслеживали исходы пациентов, выписанных под амбулаторное наблюдение. Конечными точками являлись все случаи смерти и рецидивов ТЭЛА. Статистическую обработку результатов осуществляли с помощью пакета программ MedCalc Version 16.2.1 (Softwa, Бельгия). Результаты: Годовые исходы были определены у 161 пациента. Фатальный исход в течение года после выписки из стационара наступил у 22 (13,6%) больных ТЭЛА: у 45,5% по причине рецидива ТЭЛА, у 22,7% — онкологической патологии, у 13,6% — из-за острого нарушения мозгового кровообращения (ОНМК). Развитие летальных исходов было ассоциировано с такими факторами, как пожилой возраст, наличие ишемической болезни сердца, злокачественных новообразований, застойной сердечной недостаточности, ОНМК, а также со снижением глобальной сократимости миокарда левого желудочка, высоким риском по шкале PESI (англ. Pulmonary Embolism Severity Index) и отказом от антикоагулянтной терапии в течение первых 6 мес. Рецидив ТЭЛА в течение года наблюдения выявлен в 11,2% случаев и был связан с наличием тромбоза глубоких вен нижних конечностей, нижней полой вены и подвздошных вен, застойной сердечной недостаточностью и дилатацией правых отделов сердца. Установлено, что отказ от антикоагулянтной терапии в течение 11 мес после первичного эпизода повышает риск развития рецидива ТЭЛА. Заключение: У пациентов с ТЭЛА в течение первого года наблюдения летальный исход развился в 13,6% случаев, а рецидив ТЭЛА — в 11,2%. Наиболее значимым неблагоприятным фактором, связанным с данными конечными точками, являлся отказ от антикоагулянтной терапии ранее 6 мес после эпизода ТЭЛА. Objectives: to study the incidence, causes and factors associated with adverse outcomes in patients with pulmonary embolism (PE) during the year of observation. Patients/Methods: The single-center prospective follow-up register included 185 patients with PE. Standard examination was carried out; the diagnosis was confirmed by multispiral computed tomography. During follow-up period of 12 months we tracked outpatient outcomes. The endpoints were all-cause mortality and PE relapses. Statistical analysis was performed by MedCalc Version 16.2.1 software package (Softwa, Belgium). Results: Twelve-month outcomes were determined in 161 patients. Post-discharge fatal outcome within a year occurred in 22 (13.6%) patients with PE: in 45.5% due to PE relapse, in 22.7% due to oncological pathology, in 13.6% because of acute stroke. Lethal outcomes were associated with elderly age, ischemic heart disease, malignant neoplasms, congestive heart failure, stroke, reduction of left ventricular global myocardial contractility, a high risk according to PESI (Pulmonary Embolism Severity Index) scale and the refusal of anticoagulant therapy during the first 6 months. Within a year of observation PE relapse was detected in 11.2% of patients and was associated with deep vein thrombosis of the lower limbs, inferior vena cava and iliac veins, congestive heart failure and dilatation of right heart compartments. Refusal of anticoagulant therapy within 11 months after the initial episode increased the risk of PE relapse. Conclusions: In patients with PE during the first year of observation a fatal outcome occurred in 13.6% patients with PE and PE relapse — in 11.2%. Refusal of anticoagulant therapy earlier than 6 months after the episode of PE was the most significant adverse factor associated with these endpoints.
- Open Access
- 10 July 2020
- Published by Cardiology Research Institute in The Siberian Journal of Clinical and Experimental Medicine
- Vol. 35 (2) , 157-162
Positive impact of cardiac contractile modulation on myocardial contractility and left ventricular synchronization in a patient with a left ventricular noncompaction
The article provides a clinical case of a 58-year-old man with the fi rst clinical manifestation of chronic heart failure in the presence of a signifi cant decrease in the left ventricular ejection fraction. Left ventricular non-compaction cardiomyopathy was diagnosed by echocardiography. After 12 months, a cardiac contractility modulation device was implanted to the patient in the presence of disease progression despite optimal medical therapy. We assessed the course of disease, quality of life, exercise tolerance, and myocardial contractility of the patient before and six months after surgery. The methods of assessment were collection of patient complaints, physical examination, electrocardiography (ECG), fi lling out the Minnesota Living with Heart Failure Questionnaire (MLHFQ), sixminute walk test, spiroergometry, and echocardiography.
- 10 July 2020
- Published by Cardiology Research Institute in The Siberian Journal of Clinical and Experimental Medicine
- Vol. 35 (2) , 157-162
Open AccessPositive impact of cardiac contractile modulation on myocardial contractility and left ventricular synchronization in a patient with a left ventricular noncompaction
The article provides a clinical case of a 58-year-old man with the fi rst clinical manifestation of chronic heart failure in the presence of a signifi cant decrease in the left ventricular ejection fraction. Left ventricular non-compaction cardiomyopathy was diagnosed by echocardiography. After 12 months, a cardiac contractility modulation device was implanted to the patient in the presence of disease progression despite optimal medical therapy. We assessed the course of disease, quality of life, exercise tolerance, and myocardial contractility of the patient before and six months after surgery. The methods of assessment were collection of patient complaints, physical examination, electrocardiography (ECG), fi lling out the Minnesota Living with Heart Failure Questionnaire (MLHFQ), sixminute walk test, spiroergometry, and echocardiography.
- Open Access
- 11 July 2019
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 34 (2)
EFFICACY OF ATRIAL FIBRILLATION DETECTION IN CRYPTOGENIC STROKE ACCORDING TO DATA OF IMPLANTABLE LOOP RECORDERS: PILOT STUDY
Aim. To estimate the efficacy of invasive and non-invasive long-term ECG monitoring in comparison with conventional follow-up for the detection of silent atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT) in patients with a cryptogenic stroke.Methods. The randomized, prospective, two-center study enrolled 36 patients who suffered cryptogenic stroke (CS) or transient ischemic attack (TIA) without past history of AF/AFL/AT. Patients were randomized in a 1:1:1 ratio to one of the three ECG monitoring strategies: standard arrhythmia monitoring (group I, n=12), ECG-monitoring with implantable loop recorder (group II, n=12), and ambulatory noninvasive ECG monitoring (group III, n=12). The primary endpoint was the time to the first detection of AF/AFL/AT. Patients, assigned to the group I, underwent an assessment at scheduled and unscheduled visits and received ambulatory ECG monitoring 28 days and 1 year after randomization. Patients in the group II underwent implantation of Reveal XT (Medtronic, USA) with the daily remote data transmission to CareLink Network. In the group III, for long-term external monitoring, Spyder system (WEB Biotechnology, Singapore) was used for up to 28 days.Results. During the first 28 days of observation, there were no significant differences in AF detection rates between groups I, II, and III: 0 (0%), 1 (8%), and 2 (17%) cases, respectively, р=0.537. During the year of observation, AF/AFL/AT episodes were detected in 1 case (8%) in the group I, 6 cases (50%) in the group II, and 2 cases (17%) in the group III, p=0.0486. The mean time from enrollment into the study to detection of the first AF/AFL/AT episode was 67 days (15; 97) in all groups. In the groups II and III, the first arrhythmia episodes were detected by monitoring devices on days 24 and 6, respectively. In most cases, arrhythmia episodes detected by long-term monitoring were asymptomatic. Recurrent stroke or TIA events occurred in group I and III (1 case in each group), but not in the group with implantable cardiac monitors. Subgroup analysis showed that significantly higher AF/AFL/AT detection rate was associated with stroke, CHA2DS2VASc score ≥2, and the presence of hypertension. For the 12 months of follow-up, the mean AF burden in the group II was 0.4 (0.2; 0.5) hours per day (1.6%). In the patients with recurrent stroke, AF burden was 3.2% compared to 0.9% in the rest of patients.Conclusion. Detection of silent AF with implantable cardiac monitors is superior to standard and long-term external monitoring in cryptogenic stroke patients.
- 11 July 2019
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 34 (2)
Open AccessEFFICACY OF ATRIAL FIBRILLATION DETECTION IN CRYPTOGENIC STROKE ACCORDING TO DATA OF IMPLANTABLE LOOP RECORDERS: PILOT STUDY
Aim. To estimate the efficacy of invasive and non-invasive long-term ECG monitoring in comparison with conventional follow-up for the detection of silent atrial fibrillation (AF)/atrial flutter (AFL)/atrial tachycardia (AT) in patients with a cryptogenic stroke.Methods. The randomized, prospective, two-center study enrolled 36 patients who suffered cryptogenic stroke (CS) or transient ischemic attack (TIA) without past history of AF/AFL/AT. Patients were randomized in a 1:1:1 ratio to one of the three ECG monitoring strategies: standard arrhythmia monitoring (group I, n=12), ECG-monitoring with implantable loop recorder (group II, n=12), and ambulatory noninvasive ECG monitoring (group III, n=12). The primary endpoint was the time to the first detection of AF/AFL/AT. Patients, assigned to the group I, underwent an assessment at scheduled and unscheduled visits and received ambulatory ECG monitoring 28 days and 1 year after randomization. Patients in the group II underwent implantation of Reveal XT (Medtronic, USA) with the daily remote data transmission to CareLink Network. In the group III, for long-term external monitoring, Spyder system (WEB Biotechnology, Singapore) was used for up to 28 days.Results. During the first 28 days of observation, there were no significant differences in AF detection rates between groups I, II, and III: 0 (0%), 1 (8%), and 2 (17%) cases, respectively, р=0.537. During the year of observation, AF/AFL/AT episodes were detected in 1 case (8%) in the group I, 6 cases (50%) in the group II, and 2 cases (17%) in the group III, p=0.0486. The mean time from enrollment into the study to detection of the first AF/AFL/AT episode was 67 days (15; 97) in all groups. In the groups II and III, the first arrhythmia episodes were detected by monitoring devices on days 24 and 6, respectively. In most cases, arrhythmia episodes detected by long-term monitoring were asymptomatic. Recurrent stroke or TIA events occurred in group I and III (1 case in each group), but not in the group with implantable cardiac monitors. Subgroup analysis showed that significantly higher AF/AFL/AT detection rate was associated with stroke, CHA2DS2VASc score ≥2, and the presence of hypertension. For the 12 months of follow-up, the mean AF burden in the group II was 0.4 (0.2; 0.5) hours per day (1.6%). In the patients with recurrent stroke, AF burden was 3.2% compared to 0.9% in the rest of patients.Conclusion. Detection of silent AF with implantable cardiac monitors is superior to standard and long-term external monitoring in cryptogenic stroke patients.